Real-world outcomes of direct oral anticoagulants versus warfarin in patients with single-positive antiphospholipid antibody syndrome: A trinetx cohort analysis
Cohort analysis shows DOACs lower risks of bleeding and stroke in single-positive antiphospholipid syndrome, indicating potential alternatives to warfarin.
Key Points
To evaluate the safety and efficacy of direct oral anticoagulants compared to warfarin in patients with single-positive antiphospholipid syndrome.
Retrospective cohort studies using TriNetX network.
Included adults with single-positive antiphospholipid antibodies (aCL, LAC, B2GP1).
Compared outcomes between patients initiated on DOACs and those on warfarin using propensity score matching.
DOACs showed lower risks of gastrointestinal bleed and ischemic stroke in specific cohorts.
Higher risk of myocardial infarction observed with DOACs in aCL-positive patients.
DOACs demonstrated similar safety profiles to warfarin for most outcomes.